Drug companies and their development partners are employing new models and methods aimed at improving clinical success rates, according to the April R&D management report from Tufts Center for the Study of Drug Development. “The research-based drug industry is racing to boost its research pipelines, as existing patents expire and development times continue to lengthen,” said Tufts CSDD director Kenneth I Kaitin. “Drug companies are exploring new approaches to product devel...